These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38901497)

  • 1. Oncolytic virotherapy improves immunotherapies targeting cancer stemness in glioblastoma.
    Keshavarz M; Dianat-Moghadam H; Ghorbanhosseini SS; Sarshari B
    Biochim Biophys Acta Gen Subj; 2024 Sep; 1868(9):130662. PubMed ID: 38901497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells.
    Soroush A; Shahhosseini R; Ghavamikia N; Hjazi A; Roudaki S; KhalatbariLimaki M; Mirbolouk M; Pakmehr S; Karimi P
    Cell Biochem Funct; 2024 Jun; 42(4):e4055. PubMed ID: 38856033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
    Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
    Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
    Kardani K; Sanchez Gil J; Rabkin SD
    Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
    Sgubin D; Wakimoto H; Kanai R; Rabkin SD; Martuza RL
    Stem Cells Transl Med; 2012 Apr; 1(4):322-32. PubMed ID: 23197811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
    Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF
    mBio; 2018 Sep; 9(5):. PubMed ID: 30228241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.
    Nair S; Mazzoccoli L; Jash A; Govero J; Bais SS; Hu T; Fontes-Garfias CR; Shan C; Okada H; Shresta S; Rich JN; Shi PY; Diamond MS; Chheda MG
    JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33232299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Zika Virus: New Option for Glioblastoma Treatment.
    Zhou C; Chen Q; Chen Y; Qin CF
    DNA Cell Biol; 2023 Jun; 42(6):267-273. PubMed ID: 36350682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.
    Stergiopoulos GM; Concilio SC; Galanis E
    Curr Treat Options Oncol; 2024 Jul; 25(7):952-991. PubMed ID: 38896326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

  • 13. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
    Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
    EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting role of glioma stem cells for glioblastoma multiforme.
    Zhang X; Zhang W; Mao XG; Zhen HN; Cao WD; Hu SJ
    Curr Med Chem; 2013; 20(15):1974-84. PubMed ID: 23317162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
    Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
    Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
    Crupi MJF; Bell JC; Singaravelu R
    Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
    Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
    Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
    Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
    Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.